Medpace CEO sells 42,783 shares in August window

Medpace Holdings, Inc. (MEDP) reported that President & CEO August J. Troendle sold common stock in two open-market transactions.

Rhea-AI Filing Summary

Medpace Holdings, Inc. (MEDP) reported that President & CEO August J. Troendle sold common stock in two open-market transactions. On August 20, 2026, he sold 27,174 shares at a weighted average price of $618.79 per share, and on August 19, 2026, he sold 15,609 shares at a weighted average price of $606.47 per share. Both were executed pursuant to a limit order during an open window period and involved multiple trades within disclosed price ranges. Following these transactions, Troendle is reported to indirectly hold 4,733,019 shares through Medpace Investors, LLC, where he has sole voting and investment control, while disclaiming beneficial ownership except to the extent of his pecuniary interest.

Insider Trade Summary

Net Seller: 42,783 shares

Net Sell 3 txns

Insider Troendle August J.

Role President & CEO

Sold 42,783 shs ($26.28M)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F3	27,174	$618.79	$16.81M
Sale	Common Stock F1, F2	15,609	$606.47	$9.47M
holding	Common Stock F4	--	--	--

Holdings After Transaction: Common Stock — 561,195 shares (Direct); Common Stock — 4,733,019 shares (Indirect, By Medpace Investors, LLC)

Footnotes (4)

1. F1. The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.
2. F2. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $601.29 to $611.42. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
3. F3. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $606.20 to $626.51. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
4. F4. The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Key Figures

Shares sold on August 19, 2026: 15,609 shares Weighted average sale price on August 19, 2026: $606.47 per share Price range on August 19, 2026 sales: $601.29–$611.42 per share +5 more

8 metrics

Shares sold on August 19, 2026 15,609 shares Open-market sale of Medpace common stock by August J. Troendle

Weighted average sale price on August 19, 2026 $606.47 per share Sale of 15,609 Medpace common shares

Price range on August 19, 2026 sales $601.29–$611.42 per share Multiple transactions comprising the weighted average price

Shares sold on August 20, 2026 27,174 shares Open-market sale of Medpace common stock by August J. Troendle

Weighted average sale price on August 20, 2026 $618.79 per share Sale of 27,174 Medpace common shares

Price range on August 20, 2026 sales $606.20–$626.51 per share Multiple transactions comprising the weighted average price

Total shares sold 42,783 shares Combined August 19–20, 2026 sales by August J. Troendle

Indirectly held shares through Medpace Investors, LLC 4,733,019 shares Indirect holdings of Medpace common stock after reported transactions

Key Terms

limit order, weighted average price, indirectly beneficially own, pecuniary interest

4 terms

limit order market

"transactions ... were effected pursuant to a limit order placed"

A limit order is an instruction to buy or sell a stock only at a specific price or better, giving you control over the exact price you pay or receive. It matters to investors because it acts like a price guard—similar to setting a maximum you’ll pay for an item at a store—so you avoid unexpected prices, though the trade may not happen if the market never reaches your limit.

weighted average price financial

"The reported price is a weighted average price. These shares were sold"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

indirectly beneficially own financial

"may be deemed to indirectly beneficially own the securities"

pecuniary interest financial

"disclaims beneficial ownership of such securities except to the extent of his pecuniary interest"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did MEDP President & CEO August J. Troendle report?

August J. Troendle reported selling 42,783 Medpace (MEDP) common shares in two open-market transactions on August 19–20, 2026, at weighted average prices of $606.47 and $618.79 per share, executed pursuant to a limit order during an open trading window.

How many MEDP shares did August J. Troendle sell on August 19, 2026?

On August 19, 2026, August J. Troendle sold 15,609 Medpace (MEDP) common shares at a weighted average price of $606.47 per share, with individual trades executed in a price range from $601.29 to $611.42.

How many MEDP shares did August J. Troendle sell on August 20, 2026?

On August 20, 2026, August J. Troendle sold 27,174 Medpace (MEDP) common shares at a weighted average price of $618.79 per share, with individual trades executed in a price range from $606.20 to $626.51.

Were the recent MEDP insider stock sales made under a trading plan?

The filing for Medpace (MEDP) states that the transactions were effected pursuant to a limit order placed during an open window period. The Rule 10b5-1 checkbox is not marked as being under such a plan, and no footnote references a 10b5-1 trading plan.

How many MEDP shares does August J. Troendle indirectly hold after these transactions?

After the reported transactions, August J. Troendle is reported as indirectly holding 4,733,019 Medpace (MEDP) common shares through Medpace Investors, LLC, where he has sole voting and investment control, while disclaiming beneficial ownership except to the extent of his pecuniary interest.

What price ranges applied to August J. Troendle’s MEDP stock sales?

For Medpace (MEDP), the August 19, 2026 sales occurred in a range of $601.29–$611.42 per share, and the August 20, 2026 sales occurred in a range of $606.20–$626.51 per share. Each day’s reported price is a weighted average price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/21/2026 - 04:13 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Troendle August J.

(Last) (First) (Middle)

C/O MEDPACE HOLDINGS, INC.

5375 MEDPACE WAY

(Street)

CINCINNATI OHIO 45227

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medpace Holdings, Inc. [ MEDP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/19/2026		S(1)		15,609	D	$606.47(2)	588,369	D
Common Stock	08/20/2026		S(1)		27,174	D	$618.79(3)	561,195	D
Common Stock								4,733,019	I	By Medpace Investors, LLC(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.

2. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $601.29 to $611.42. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

3. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $606.20 to $626.51. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

4. The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

	/s/Stephen P. Ewald, Attorney-in-Fact for August J. Troendle	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)